(Q33857482)

29 July 2017

1 reference

title

Targeting the HIV-protease in AIDS therapy: a current clinical perspective (English)

1 reference

29 July 2017

A G Tomasselli

1

1 reference

29 July 2017

R L Heinrikson

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Biochimica et Biophysica Acta

29 July 2017

published in

1 reference

29 July 2017

volume

1477

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

189-214

1 reference

Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

The use of combination antiretroviral therapy in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

The structure and function of the aspartic proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

A structural model for the retroviral proteases.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

An alternate-subsite-coupled model for predicting HIV protease cleavage sites in proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Models for the incubation of AIDS and variations according to age and period

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

The Evaluation of Non-Viral Substrates of the HIV Protease as Leads in the Design of Inhibitors for Aids Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Recent advances in the design of HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

1 reference

7 January 2021

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Recovery of the immune system with antiretroviral therapy: the end of opportunism?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

HIV researchers air new findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

HIV drug resistance tests are here to stay

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

Latent reservoirs for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

HIV-1 and HAART: a time to cure, a time to kill

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900273-3

7 January 2021

10.1016/S0167-4838(99)00273-3

Identifiers

DOI

1 reference

29 July 2017

1 reference